MYRIAD GENETICS INC (MYGN)

US62855J1043 - Common Stock

23.5  +0.57 (+2.49%)

After market: 23.19 -0.31 (-1.32%)

Fundamental Rating

3

Taking everything into account, MYGN scores 3 out of 10 in our fundamental rating. MYGN was compared to 597 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.



3

1. Profitability

1.1 Basic Checks

MYGN had negative earnings in the past year.
MYGN had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MYGN reported negative net income in multiple years.
MYGN had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -23.88%, MYGN is in the better half of the industry, outperforming 79.32% of the companies in the same industry.
With a decent Return On Equity value of -40.15%, MYGN is doing good in the industry, outperforming 73.73% of the companies in the same industry.
Industry RankSector Rank
ROA -23.88%
ROE -40.15%
ROIC N/A
ROA(3y)-8.54%
ROA(5y)-2.79%
ROE(3y)-12.39%
ROE(5y)-4.59%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MYGN has a better Gross Margin (68.89%) than 83.22% of its industry peers.
MYGN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y-1.7%

3

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYGN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MYGN has more shares outstanding
There is no outstanding debt for MYGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.12 indicates that MYGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of MYGN (2.12) is better than 67.46% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that MYGN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, MYGN is not doing good in the industry: 63.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 2.12
ROIC/WACCN/A
WACC10.85%

2.3 Liquidity

A Current Ratio of 1.27 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN has a worse Current ratio (1.27) than 87.63% of its industry peers.
A Quick Ratio of 1.15 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN has a Quick ratio of 1.15. This is amonst the worse of the industry: MYGN underperforms 87.12% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.15

4

3. Growth

3.1 Past

MYGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -120.00%.
Looking at the last year, MYGN shows a quite strong growth in Revenue. The Revenue has grown by 11.04% in the last year.
Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -1.42% on average per year.
EPS 1Y (TTM)-120%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q84.21%
Revenue 1Y (TTM)11.04%
Revenue growth 3Y-7.28%
Revenue growth 5Y-1.42%
Revenue growth Q2Q22.7%

3.2 Future

MYGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.40% yearly.
MYGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.52% yearly.
EPS Next Y-3.13%
EPS Next 2Y41.17%
EPS Next 3Y44%
EPS Next 5Y46.4%
Revenue Next Year12.1%
Revenue Next 2Y10.58%
Revenue Next 3Y9.66%
Revenue Next 5Y9.52%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

MYGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MYGN's earnings are expected to grow with 44.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.17%
EPS Next 3Y44%

0

5. Dividend

5.1 Amount

No dividends for MYGN!.
Industry RankSector Rank
Dividend Yield N/A

MYRIAD GENETICS INC

NASDAQ:MYGN (2/27/2024, 7:00:01 PM)

After market: 23.19 -0.31 (-1.32%)

23.5

+0.57 (+2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.08B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.88%
ROE -40.15%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 68.89%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.27
Quick Ratio 1.15
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-120%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-3.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.04%
Revenue growth 3Y-7.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y